Patents by Inventor Anne JEREMIAS

Anne JEREMIAS has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Lipid production
    Patent number: 11236372
    Abstract: The present invention relates to at least one cell for producing at least one lipid with general formula II from at least one carbon substrate, wherein R1 and R2 independently of one another comprises identical or different organic radicals each with 5 to 13 carbon atoms, wherein the cell is a non-pathogenic cell that is genetically modified to increase the heterologous expression relative to the wild type cell of: an enzyme (E2) capable of converting 3-hydroxyalkanoyl-3-hydroxyalkanoyl-CoA/ACP or 3-(3-hydroxyalkanoyloxy)alkanoic acid (HAA) and NDP-glucose into ?-D-glucopyranosyl-3-hydroxyalkanoyl-3-hydroxyalkanoate.
    Type: Grant
    Filed: February 8, 2019
    Date of Patent: February 1, 2022
    Assignee: Evonik Operations GmbH
    Inventors: Mirja Wessel, Steffen Schaffer, Anne Jeremias, Martin Schilling, Hans Henning Wenk
  • MIXTURE COMPOSITION COMPRISING GLUCOLIPIDS
    Publication number: 20210371773
    Abstract: The invention relates to a mixture composition comprising glucolipids, to its use for producing formulations and to formulations comprising this mixture composition.
    Type: Application
    Filed: February 8, 2019
    Publication date: December 2, 2021
    Applicant: Evonik Operations GmbH
    Inventors: Kathrin Daniela Brandt, Stefan Julian Liebig, Hans Henning Wenk, Maciej Olek, Martin Schilling, Steffen Schaffer, Mirja Wessel, Anne Jeremias
  • LIPID PRODUCTION
    Publication number: 20200407761
    Abstract: The present invention relates to at least one cell for producing at least one lipid with general formula II from at least one carbon substrate, wherein R1 and R2 independently of one another comprises identical or different organic radicals each with 5 to 13 carbon atoms, wherein the cell is a non-pathogenic cell that is genetically modified to increase the heterologous expression relative to the wild type cell of: an enzyme (E2) capable of converting 3-hydroxyalkanoyl-3-hydroxyalkanoyl-CoA/ACP or 3-(3-hydroxyalkanoyloxy)alkanoic acid (HAA) and NDP-glucose into ?-D-glucopyranosyl-3-hydroxyalkanoyl-3-hydroxyalkanoate.
    Type: Application
    Filed: February 8, 2019
    Publication date: December 31, 2020
    Applicant: EVONIK OPERATIONS GMBH
    Inventors: Mirja WESSEL, Steffen SCHAFFER, Anne JEREMIAS, Martin SCHILLING, Hans Henning WENK